Lung problems

Scleroderma symptoms can vary greatly from person to person, however, up to half of all scleroderma patients also develop lung problems.^1,2 Early treatment can make a huge difference, so it is important to track any symptoms you notice and discuss them with your doctor.^1-5

2 min read

What are the symptoms of lung problems?

Symptoms of lung problems in scleroderma patients are frequently gradual and often overlooked, with patients simply thinking they’re tired or out of shape.^1,3,4,6 However, certain changes can suggest a lung problem, so it is vital to pay attention to your body. Respiratory symptoms can be unspecific, so a simple symptom evaluation may not always help a doctor make a differential diagnosis.^1,6,7The Symptom Tracker can help your doctor to quickly diagnose any problem.

Track your symptoms

When you know what to look for, it’s straightforward to track your symptoms. Discover more with our symptom tracker.

Symptom tracker

Symptoms^1,6,7

Digestive problems (IBS symptoms)

Swallowing problems (dysphagia)

Heart palpitations

Feeling out of breath when doing simple tasks like climbing the stairs

Dry cough you can’t get rid of

Feeling dizzy (vertigo)

Chest pain

Difficulty taking deep breaths

Feeling your chest is tight

Feeling very tired when going about your normal day

These symptoms could be a sign of lung or heart problems.¹ If you notice any of these symptoms, talk to your doctor as soon as possible. They will be able to perform the necessary tests to ensure the right diagnosis, so you quickly get the expert help and support you need.

Scleroderma may affect your lungs in two key ways:^2,3,6,8-12

3-4-lung_fibrosis_ild_infographic_more_than_scleroderma_boehringer_ingelheim_1

3-4-pulmonary_arterial_hypertension_pah_infographic_more_than_scleroderma_boehringer_ingelheim_0

Up to half of people who will be affected by lung problems develop symptoms within 3 years of being diagnosed with scleroderma.^2,6-9

What can you do to help be on top of your symptoms?^4,5,13

Regular testing of your lung function (at least annually)

Pay attention to your body and the warning signs it gives you

Track your symptoms

Talk to your doctor

With lung problems from scleroderma, early action is essential. Your doctor can advise you on the available treatments that can slow down its progression. However, scientists have not yet discovered a cure for scleroderma or ILD. In the meantime, your doctor might suggest medications that make your symptoms easier to manage.²

Lung tests for scleroderma

What to expect at lung tests

People with scleroderma should have their lung tested regularly. Learn more about the type of tests your doctor may use.

Lung tests for scleroderma

Interstitial lung disease (ILD)

What is ILD

Lung fibrosis (interstitial lung disease [ILD]) is a serious complication of scleroderma. Find out more here.

Interstitial lung disease (ILD)

Pulmonary arterial hypertension (PAH)

What is PAH

Pulmonary arterial hypertension (PAH) can affect some people with scleroderma, but it can be managed.

Pulmonary arterial hypertension (PAH)

Scleroderma & Raynaud’s UK. Organs. Available: https://www.sruk.co.uk/scleroderma/scleroderma-and-your-body/organs/ [Accessed December 2021].
Solomon J et al. Scleroderma lung disease. Eur Respir Rev 2013;127:6–19.
Denton C and Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011;20(122):270–76.
Proudman S, et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Int Med Journal 2007;37:485–94.
Coghlan J, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340–9.
Mayo Clinic. Pulmonary hypertension. Updated March 2016. Available at: https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/symptoms-causes/syc-20350697 [Accessed December 2021].
Willems L, et al. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis in five European countries. Clin Exp Rheumatol 2014;32(S86):S88–93.
Scleroderma of the lungs. Royal Bromptom & Harefield NHS Foundation Trust. Available at: https://www.rbht.nhs.uk/our-services/scleroderma [Accessed December 2021].
Steen V, et al. Severe restrictive lunf disease in systemic sclerosis. Arthritis Rheum 1994;66(6):1625–35.
Nihtyanova S, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum 2014;66(6):1625–35.
Jaeger V, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSRAT study. PLoS One 2016;11(10):e0163894.
McNearney T, et al. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioural factors. Arthritis Rheum 2007;57(2):318–26.
McLaughlin V, et al. Expert consensus document on pulmonary hypertension. J Am Coll Cardiol 2009;53(17):1573–1619.